Relay Therapeutics, Inc. (RLAY)
16.28
-1.02
(-5.90%)
USD |
NASDAQ |
Oct 16, 16:00
16.20
-0.08
(-0.49%)
After-Hours: 20:00
Relay Therapeutics Cash from Investing (Quarterly) : -353.03M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -353.03M |
| March 31, 2026 | 32.90M |
| December 31, 2025 | 35.46M |
| September 30, 2025 | 39.72M |
| June 30, 2025 | 75.15M |
| March 31, 2025 | 42.46M |
| December 31, 2024 | 29.00M |
| September 30, 2024 | -126.16M |
| June 30, 2024 | 45.55M |
| March 31, 2024 | 10.53M |
| December 31, 2023 | 59.68M |
| September 30, 2023 | 71.36M |
| June 30, 2023 | 51.28M |
| March 31, 2023 | 75.31M |
| December 31, 2022 | -146.94M |
| Date | Value |
|---|---|
| September 30, 2022 | 27.19M |
| June 30, 2022 | 43.39M |
| March 31, 2022 | -112.38M |
| December 31, 2021 | -292.74M |
| September 30, 2021 | 20.79M |
| June 30, 2021 | 26.07M |
| March 31, 2021 | -233.62M |
| December 31, 2020 | -76.42M |
| September 30, 2020 | 20.07M |
| June 30, 2020 | 87.65M |
| March 31, 2020 | 50.37M |
| December 31, 2019 | 35.90M |
| September 30, 2019 | 7.076M |
| June 30, 2019 | -358.85M |
| March 31, 2019 | -3.144M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | 0.00 |
| TG Therapeutics, Inc. | 1.03M |
| Karyopharm Therapeutics, Inc. | -10.04M |
| Spyre Therapeutics, Inc. | -297.90M |
| Akebia Therapeutics, Inc. | -4.079M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -54.11M |
| Cash from Financing (Quarterly) | 323.74M |
| Free Cash Flow | -212.20M |
| Free Cash Flow Per Share (Quarterly) | -0.2667 |
| Free Cash Flow to Equity (Quarterly) | -53.20M |
| Free Cash Flow to Firm (Quarterly) | -54.11M |
| Free Cash Flow Yield | -7.16% |